We are Methyl [(dimethoxyphosphoryl)sulfanyl]acetate CAS:57212-78-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Methyl [(dimethoxyphosphoryl)sulfanyl]acetate
Synonyms:Methyl [(dimethoxyphosphoryl)sulfanyl]acetate
O,O-dimethyl-S-(benzene sulphonyl)dithiophosphate
Physical and Chemical Properties:
Density 1.294g/cm3
Boiling Point 247ºC at 760mmHg
Molecular Formula C5H11O5PS
Molecular Weight 214.17700
Flash Point 103.2ºC
Index of Refraction 1.46
Appearance:Colorless to light yellow liquid
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Omethoate(CAS:1113-02-6).

Methyl [(dimethoxyphosphoryl)sulfanyl]acetate

Related News: The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.5-tert-butyl-1,2-dihydro-1,2,4-triazole-3-thione CAS:38449-51-3 Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.1028252-16-5 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?2,3-dietilpirazina CAS:15707-24-1 With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.

Related Products
Product Name
(R)-BoroLeu-(+)-Pinanediol-HCl View Details
Chitosan 2-hydroxypropanoate (salt) Cas:66267-50-3 View Details
(S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile Hydrochloride Cas:1306763-57-4 View Details
(1R)-1-phenylethanamine manufacturer 3-Buten-2-ol Cas:598-32-3 manufacturer 2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide manufacturer Levomefolic Acid Cas:NO: 31690-09-2 manufacturer (1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine Cas:608141-42-0 manufacturer